Sunday, October 5, 2025

Revisiting Asbestos Related Injuries (and other toxic contaminants)

 PRESS RELEASE 

DETOXSCAN™ Program to Cover Diagnostic Front in Environmental Exposure Care

New York, NY (October 2025) — Twenty-four years after 9/11, thousands of responders and residents are still living with the delayed effects of toxic dust exposure. To address the growing wave of asbestos-related and environmental illnesses, diagnostic imaging specialist Dr. Robert L. Bard has introduced DETOXSCAN™, a precision-imaging program designed to identify early signs of toxin-induced disorders in the skin, lungs, liver, and kidneys.

The Hidden Legacy of Dust Exposure

The collapse of the Twin Towers released more than 400,000 tons of pulverized debris containing asbestos, silica, lead, mercury, benzene, and microplastics.¹ Over 90,000 first responders were directly exposed, and studies confirm continuing increases in respiratory disease, autoimmune disorders, and cancers—including mesothelioma, whose incidence among responders remains nearly 11 times higher than normal populations.²,³

“Dust is not inert—it’s biologically active,” says Dr. Bard. “It carries fibrogenic and carcinogenic particles that continue to inflame tissues decades after exposure.”

But asbestos is only one piece of the modern exposure crisis. Today’s construction, demolition, and fire-recovery environments contain mold spores, volatile organic compounds (VOCs), heavy metals, and combustion byproducts, each capable of triggering oxidative stress, immune dysfunction, and systemic inflammation. Workers and nearby residents frequently present with skin irritation, chronic cough, headaches, and fatigue—signs that often precede liver fibrosis, renal damage, or malignancy.

 

DETOXSCAN™: Imaging the Unseen

Dr. Bard’s DETOXSCAN™ applies high-resolution ultrasound, Doppler flow studies, elastography, and thermography to reveal tissue reactions from toxic exposures long before they appear in laboratory tests. By mapping inflammation, vascular disruption, and fibrosis, clinicians can monitor detoxification progress and identify those at risk for chronic illness.

“The skin is a living dashboard of toxic stress,” explains Dr. Bard. “With imaging and AI analytics, we can now translate what it shows into quantifiable clinical data.”

Using pattern recognition, DETOXSCAN™ differentiates exposure-related inflammation from infection or autoimmune disease. The system’s growing image database—built in collaboration with occupational health specialists—links diagnostic visuals to toxin-specific biomarkers, creating one of the first AI-enabled archives of exposure pathology.

Advocacy, Prevention, and Detox Science

The initiative pays tribute to the work of individuals like Anne-Marie Principe, a 9/11 health advocate who continues to champion screening and care for responders. It also honors Dr. David Root, whose clinical detoxification protocols using sauna-niacin therapy demonstrated measurable reductions in stored industrial toxins.⁴ DETOXSCAN™ incorporates such research within a diagnostic framework, allowing clinicians to evaluate the biological results of detox interventions.

“Detoxification isn’t fringe—it’s prevention,” says Dr. Bard. “By integrating imaging, lab biomarkers, and exposure history, we can help protect workers and families long before disease develops.”


A National Model for Exposure Medicine

Beyond New York, similar toxic exposure patterns have been documented among wildfire crews, industrial reclamation teams, and urban demolition workers.⁵ Dr. Bard envisions DETOXSCAN™ as a national surveillance model—merging imaging diagnostics with environmental medicine to track the biological footprint of pollution and occupational hazards.

“The dust of 9/11 taught us that toxic exposure is a slow-moving disaster,” Dr. Bard concludes. “Our mission now is to detect the invisible damage early—and give survivors a chance to heal.”


References (AMA Style)

1.     Prezant DJ, et al. Respiratory health of 9/11 rescue workers: a 20-year perspective. Lancet Respir Med. 2022;10(8):785-796.

2.     Carbone M, Yang H. Molecular mechanisms of asbestos carcinogenesis. Clin Cancer Res. 2012;18(3):598-604.

3.     Li J, Cone JE, Kahn AR, et al. Cancer incidence among World Trade Center rescue and recovery workers, 2002-2018. JAMA Netw Open. 2022;5(9):e2230595.

4.     Root DE, Hubbard RL. The sauna-niacin detoxification method in the treatment of environmental chemical exposures. Clin Toxicol. 1992;30(5):653-665.

5.     Bard RL, Valle-Montoya L, Goetze L. Image-guided diagnostics for environmental exposure. HealthTech Reporter. 2024;2(3):18-25.

Friday, October 3, 2025

Ultrasound Imaging and Detox Monitoring for First Responders | Dr. Leslie Valle-Montoya

3 Patients Scanned with the Terason 3200T Ultrasound (10/3/2025)  

PATIENT 1: Thyroid Ultrasound Impression
Ultrasound imaging of the thyroid gland demonstrates that both lobes are normal in size and contour, with no focal masses or nodules appreciated. The isthmus appears normal and maintains expected thickness, and the distal portions of the right and left lobes show preserved structural continuity without distortion or mass effect. Color Doppler reveals no abnormal vascularity.

Evaluation of the adjacent carotid arteries shows a smooth intimal lining with no evidence of intimal-medial thickening or plaque formation. Arterial flow appears laminar and unremarkable.

However, the echotexture of the thyroid parenchyma is notably altered. In a healthy thyroid, the tissue typically displays a bright, uniform, finely granular “white” echogenic pattern. In this study, the thyroid demonstrates a more heterogeneous, hypoechoic (gray) pattern throughout both lobes. This reduction in normal echogenic brightness suggests early or ongoing inflammatory change. These sonographic characteristics may be consistent with autoimmune thyroiditis (e.g., Hashimoto’s thyroiditis) or early fibrotic remodeling of the gland. Correlation with thyroid function testing (TSH, TPO antibodies, TgAb, and Free T4) is recommended to determine clinical significance.

No suspicious cervical lymph nodes are visualized, and surrounding soft tissues appear unremarkable.

Conclusion: Normal thyroid size and vascular patterns with preserved carotid intima. Diffuse hypoechogenicity and loss of normal glandular brightness raise suspicion for autoimmune inflammation or fibrosis. Clinical and laboratory correlation advised.




PATIENT 2: Thyroid Ultrasound Impression —

Transverse ultrasound imaging of the right thyroid lobe is unremarkable, showing normal size, contour, and echotexture with no suspicious nodules or parenchymal abnormalities. Vascular flow is within normal limits.

In the left thyroid lobe, at the mid-gland level, there is a small cystic lesion measuring approximately 1 × 2 mm. While many thyroid cysts represent benign incidental findings, this particular lesion is notable for the presence of internal micro-calcification, which classifies it as a complex cystic lesion rather than a simple cyst. Micro-calcifications can occasionally be associated with early or evolving papillary thyroid changes, and therefore carry greater diagnostic weight than a typical simple cyst.

Given these characteristics, further evaluation is warranted. Elastography (to evaluate lesion stiffness) and LER (likely referring to a local elastographic ratio or targeted evaluation region) are recommended as part of the next diagnostic step to better characterize this lesion’s biological behavior.

Follow-up Guidance:
Due to the presence of calcification within the cyst, short-interval monitoring is advised. A repeat ultrasound at 6 months, followed by annual surveillance, is recommended to assess stability, resolution, or progression. Earlier re-evaluation may be indicated if there are changes in thyroid function, onset of symptoms, or abnormal laboratory markers (TSH, TPO, TgAb).

Conclusion:
Normal right lobe. Left mid-gland 1 × 2 mm complex cystic lesion with internal micro-calcification. Recommend elastography and short-interval follow-up (6 months, then yearly) to monitor for any evolving pathological features.



PATIENT 3: Thyroid Ultrasound Impression 
Transverse ultrasound imaging of both thyroid lobes demonstrates a diffuse low-intensity echogenic pattern, most prominent in the ventral (anterior) portion of each lobe. In a normal thyroid, the parenchyma should appear uniformly bright with a fine, granular texture. In this case, the reduced echogenicity suggests early fibrotic change or chronic inflammatory remodeling of the thyroid tissue.

No focal cystic lesions, nodules, or solid masses are identified. The overall gland architecture is preserved without distortion or displacement of surrounding structures. These sonographic findings raise the possibility of an autoimmune thyroid process, such as early Hashimoto’s thyroiditis, even in the absence of a discrete mass.

Recommended Next Steps:
To more fully characterize tissue stiffness and vascular patterns, the following are advised:

  • Elastography to quantify parenchymal rigidity and assess for diffuse fibrosis

  • Doppler or “ULAR flow” assessment to evaluate low vascularity, a feature sometimes associated with chronic autoimmune activity

Correlation with laboratory studies (TSH, Free T4, TPO antibodies, and TgAb) will further clarify whether the echotexture changes represent subclinical autoimmune disease, fibrotic remodeling, or another inflammatory etiology.

Conclusion:
Diffuse hypoechoic changes in the anterior thyroid lobes consistent with possible early fibrosis or autoimmune thyroiditis, without focal masses or cysts. Recommend elastography and vascular flow assessment, along with clinical and serologic correlation, to evaluate for autoimmune thyroid disease.



  Science News Feature 

INTEGRATIVE PROTOCOL FOR WILDFIRE & OCCUPATIONAL TOXIC EXPOSURE

As the Los Angeles wildfires continue to rage across the region, first responders once again stand at the front lines—risking not only their safety but also their long-term health. Beyond the immediate threats of heat and smoke inhalation lies a far more insidious risk: chronic exposure to toxicants and carcinogens that can silently damage vital organs and endocrine pathways.

Recognizing this, Dr. Leslie Valle-Montoya, M.D., MBA, founder of the Santa Barbara Longevity Center, Biomed Life, and the Brainwave Wellness Institute, has launched a cutting-edge diagnostic and detoxification initiative designed specifically for firefighters and emergency responders. Her program integrates ultrasound scanning—particularly of the thyroid and carotid arteries—with personalized detoxification strategies to monitor recovery, measure efficacy, and protect the cardiovascular and endocrine systems from toxic burden.


WHY FIREFIGHTERS NEED ADVANCED IMAGING

Research has shown that firefighters face a significantly increased risk of both thyroid dysfunction and cardiovascular disease due to exposure to combustion byproducts such as benzene, formaldehyde, heavy metals, and flame retardants. These compounds act as endocrine disruptors, altering thyroid hormone balance, while simultaneously promoting oxidative stress and atherosclerotic plaque formation in the carotid arteries.

“Every fire scene is essentially a chemical experiment,” explains Dr. Valle-Montoya. “Even with modern gear, inhaled particulates and dermal absorption introduce toxins that accumulate over time—impacting organs that regulate metabolism and vascular integrity. We can’t afford to wait for symptoms. Imaging allows us to see the early effects before they manifest clinically.”

Routine bloodwork alone often fails to capture these early pathophysiologic changes. Ultrasound, however, provides a real-time, non-invasive, and radiation-free window into both vascular health and endocrine structure. By combining B-mode anatomical imaging with Doppler flow assessment, clinicians can detect plaques, wall thickening, restricted flow, and thyroid nodules long before they become symptomatic or life-threatening.


THYROID AND CAROTID SCANNING

Dr. Valle-Montoya’s diagnostic approach focuses on two key imaging targets:

  1. Thyroid Ultrasound: Evaluates gland size, texture, and the presence of nodules or inflammation suggestive of autoimmune thyroiditis or neoplastic changes. For firefighters, the thyroid represents a sentinel of chemical stress, as many toxins mimic or disrupt thyroid hormone function.

  2. Carotid Doppler Ultrasound: Measures arterial wall thickness (IMT) and flow velocity to assess early signs of atherosclerosis or vascular inflammation—conditions accelerated by oxidative stress from toxic exposures.

The carotid arteries share an intimate anatomical connection with the thyroid gland, primarily through the superior thyroid artery, which branches from the external carotid to deliver blood to the gland. Because of this proximity, clinicians and surgeons must exercise precise awareness of these vascular structures during thyroid procedures to prevent vessel injury or hemorrhage. Beyond their structural relationship, studies have also shown a physiological link between thyroid activity and carotid wall thickness, indicating that thyroid hormones may play an influential role in maintaining vascular integrity and overall cardiovascular health.

Her program employs the Terason 3200T Ultrasound System, a portable, high-resolution diagnostic tool capable of advanced Doppler blood flow visualization. This allows clinicians to quantify perfusion and turbulence, tracking improvements as detox interventions restore vascular tone and reduce inflammatory markers. “The Terason platform is ideal for field diagnostics,” says Dr. Valle-Montoya. “It’s mobile, precise, and provides real-time data we can correlate with detox progress. The Doppler capability is invaluable for monitoring circulation changes during and after sauna or chelation protocols.”


Dr. Leslie periodically speaks to Fire Department leaders about her supportive detoxing initiatives

Ultrasound as a Real-Time Detox Biomonitoring Tool: Beyond detection, ultrasound plays a novel role in longitudinal detoxification monitoring—an emerging practice in integrative and environmental medicine. Dr. Valle-Montoya’s responders undergo baseline scans prior to detox initiation, followed by multi-phase follow-ups that visually document physiological responses to treatment.

These treatment phases may include:

  • Far-infrared sauna therapy to mobilize and eliminate lipophilic toxins through perspiration.

  • Chelation and antioxidant protocols (glutathione, NAC, CoQ10) to reduce oxidative stress.

  • Oxygenation and hydration therapies to enhance microcirculation and mitochondrial recovery.

By comparing pre- and post-therapy images, Dr. Valle-Montoya’s team can objectively evaluate vascular compliance, thyroid inflammation, and organ resilience—transforming detox from a subjective wellness pursuit into an evidence-based clinical process.

This methodology aligns with modern precision medicine principles: quantify, visualize, and validate. Each scan contributes to a growing dataset that may help correlate toxin exposure patterns with early vascular and endocrine pathology in firefighters, construction workers, and industrial personnel.


OCCUPATIONAL HEALTH MEETS FUNCTIONAL MEDICINE

Dr. Valle-Montoya’s expertise bridges conventional diagnostics and biological medicine—a European-inspired discipline that views the human body as a self-regulating system capable of regeneration when environmental stressors are identified and removed. Through her companies—Biomed Life and Biological Medicine Global Consulting—she trains practitioners worldwide on integrating imaging, lab diagnostics, and detox therapies into holistic treatment plans.

Her nonprofit Brainwave Wellness Institute (501c3) expands this mission to underserved and high-risk populations, including veterans, first responders, and communities affected by industrial or wildfire exposures. “We’re building a framework of care that merges compassion with technology,” she explains. “Firefighters give everything to protect us. The least we can do is provide them with the tools to protect their own biology.”


The Future of Imaging-Guided Detox

As wildfire seasons intensify and environmental toxins become unavoidable, Dr. Valle-Montoya’s model demonstrates how ultrasound imaging can redefine preventative care. By capturing early physiologic shifts in vascular flow, glandular structure, and tissue density, clinicians can make timely adjustments to detox and recovery programs.

Unlike MRI or CT scans, ultrasound is safe for repeated use, enabling progressive data collection over weeks or months. This capability transforms detoxification from a static prescription into a dynamic, measurable process—a true partnership between patient and technology.

In collaboration with initiatives such as DetoxScan International and the AngioInstitute, Dr. Valle-Montoya aims to standardize this scanning protocol, ultimately creating a national registry that links imaging biomarkers with environmental exposure outcomes. Such data could revolutionize how public health systems assess occupational risk and prevention strategies.


Conclusion: Seeing & Healing in Real Time

Dr. Leslie Valle-Montoya’s work epitomizes the evolution of modern integrative medicine—where diagnostic imaging, biological repair, and compassionate care converge. Her application of Terason-based ultrasound for first responders establishes a new paradigm of exposure awareness and recovery monitoring, allowing clinicians to visualize the body’s healing journey in real time. As she often says, “Health restoration begins with awareness. When we can see what’s happening inside, we can truly begin to heal.”




Epilogue: A Mentor’s Reflection — Dr. Robert L. Bard on Imaging, Service, and Collaboration

For over four decades, Dr. Robert L. Bard has stood at the intersection of technology and compassion—bringing advanced ultrasound diagnostics into the hands of those working on the front lines of environmental and occupational health. As a pioneer in real-time imaging and tele-interpretation, his mission has always been to extend the reach of precision diagnostics to communities and professionals most exposed to unseen dangers.

“Firefighters, rescue workers, and first responders represent the ultimate expression of public service,” Dr. Bard reflects. “They walk into danger when everyone else is running away—and often, that danger lingers long after the flames are out.”

Dr. Bard’s partnership with Dr. Leslie Valle-Montoya reflects this shared commitment to protection through knowledge. As her mentor in ultrasound imaging and telemedicine collaboration, he has witnessed her evolution as a clinician who integrates art, science, and heart into her work. Her application of portable ultrasound for monitoring detoxification progress among wildfire responders is, in his words, “a model of how 21st-century medicine should serve those who serve us.”

Through their collaboration, Dr. Bard provides remote interpretation and comparative analysis of imaging data, reinforcing the integrity of each scan while supporting the education of clinicians adopting these technologies worldwide. Their combined expertise bridges the clinical precision of diagnostic radiology with the regenerative philosophy of biological medicine, forming a partnership rooted in both science and service.

As a strong advocate for programs such as DetoxScan International and the AngioInstitute’s national outreach initiatives, Dr. Bard continues to promote early detection and longitudinal imaging as essential tools for exposure-based health monitoring. He recognizes Dr. Valle-Montoya’s leadership as “a blueprint for the future—where technology empowers doctors to visualize health restoration, not just disease.”

“Every responder deserves the same level of advanced care they provide for others,” Dr. Bard concludes. “Dr. Leslie’s work reminds us that healing is not passive—it’s participatory. By scanning, tracking, and learning from the body’s responses, we turn compassion into data and data into prevention. That’s the power of medicine when it’s led by purpose.”



Disclaimer:
Reference to the Terason® brand and its products is provided solely for informational and educational purposes. This article includes a technology review of the Terason 3200T ultrasound system, as originally featured on the HealthTech Reporter website. Its inclusion here is intended only to illustrate Dr. Leslie Valle-Montoya’s clinical use of ultrasound imaging within her detoxification and monitoring program, and does not constitute a commercial endorsement or advertisement.

Sunday, September 28, 2025

How Elastography is Revolutionizing Liver Health and Detoxification

From the 9/26 DETOXSCAN NEWS Presentation of Dr. Robert L. Bard

The liver, often referred to as the body’s master filter, quietly performs hundreds of functions vital to survival. It processes nutrients, regulates hormones, and detoxifies the bloodstream. Yet for decades, when physicians needed to assess liver health—particularly scarring or fibrosis—patients were subjected to one of medicine’s riskiest diagnostic tools: the liver biopsy. While accurate, the procedure carries a risk of uncontrolled bleeding, infection, and hospitalization.

Now, a new wave of non-invasive imaging is transforming this picture. Ultrasound elastography, a technology that measures tissue stiffness to reveal scarring deep within the liver, has become a safer, faster, and more precise alternative. As clinicians embrace this innovation, it is reshaping how doctors track toxic exposures, alcohol-related damage, hepatitis, and even the effectiveness of treatment.


The Hidden Threat of Liver Fibrosis
Liver fibrosis is the gradual build-up of scar tissue caused by injury or inflammation. Left unchecked, it can progress to cirrhosis, liver failure, or even cancer. Historically, detection has been a race against time. Blood tests often fail to pick up early disease, and biopsies only offer a “snapshot” from one tiny piece of tissue, potentially missing the bigger picture.

For decades, many cases of toxin-related liver disease—whether from alcohol, viral hepatitis, or environmental exposures—were underdiagnosed or detected too late. Physicians needed a way to see the full landscape of the liver in real time, without risking patient safety.



From Steelworks to Medicine: The Origins of Elastography
The breakthrough came from an unexpected place: industrial physics. Half a century ago in Chicago, physicists began experimenting with sound waves to test the strength of steel. They discovered that sound traveled quickly through solid, uniform metal but slowed dramatically in areas of rust or weakness.

Translating this principle to medicine, researchers realized the same applied to biological tissue. Healthy liver tissue transmits ultrasound waves smoothly, while scarred or fibrotic areas slow them down. This led to the birth of FibroScan, an early elastography device developed in the late 20th century.

Adoption spread rapidly across Europe. Italian researchers were among the first to apply FibroScan in clinical practice, quickly followed by the French, who refined it for use in patients with alcohol-related disease and viral hepatitis. What began as a niche innovation is now recognized globally as one of the most powerful tools for liver diagnostics.


Quantifying Scarring: A New Diagnostic Era
Unlike biopsies, elastography provides a quantitative measurement of liver stiffness, allowing physicians to monitor changes over time. This means clinicians can answer crucial questions:

Is the patient’s fibrosis worsening or improving?

Is a treatment regimen working?

Should the therapy be stopped or intensified?

In a matter of minutes, elastography offers clarity. A patient can leave the clinic knowing not only whether they have liver scarring, but also whether lifestyle changes or medications are making a difference.

Dr. Robert Bard, a diagnostic imaging specialist, emphasizes the value of this shift: “The test can be done in 15 minutes, without pain or risk, and gives us the ability to validate treatment. Patients no longer have to wait months or face uncertainty—we can track healing in real time.”


Applications Across Disease and Detoxification
The applications for elastography are wide-ranging.

Alcohol-Related Disease: Chronic alcohol consumption remains one of the most common causes of liver fibrosis. By measuring scarring levels, elastography allows physicians to counsel patients directly on how lifestyle changes are—or are not—protecting their liver.

Viral Hepatitis: Millions worldwide live with hepatitis B or C, often unaware of their infection until it becomes severe. Elastography enables early intervention and provides a tool for tracking response to antiviral treatments.

Toxin-Induced Fibrosis: From burn pit exposures in veterans to industrial chemical exposure in workers, toxins are an underappreciated driver of liver disease. Elastography offers a way to monitor these at-risk populations without invasive testing.

Treatment Validation: In an era where functional and integrative medicine emphasizes detoxification, elastography provides something rare—evidence. Patients using therapies such as chelation, nutritional detox, or lifestyle protocols can now see measurable changes in liver health.


Why This Matters Now
The growing burden of liver disease makes these innovations urgent. The World Health Organization estimates that more than one million people die annually from cirrhosis, and the rates of chronic liver disease continue to climb due to alcohol, obesity, and environmental toxins. Elastography does

not replace traditional medicine but enhances it. By providing early, accurate, and non-invasive insights, it bridges the gap between prevention, clinical monitoring, and functional detox strategies. It allows physicians to pivot care strategies sooner and empowers patients to take active roles in their recovery.

The Future of Liver Health
The story of elastography is a reminder of how technology reshapes medicine when physics, engineering, and clinical care intersect. What began as a tool for testing steel is now saving lives by detecting hidden scars in the body’s most resilient organ. As adoption grows worldwide, elastography stands to become the standard for liver evaluation, replacing biopsies in many cases and expanding into broader applications across kidneys, thyroid, and beyond. For patients, it means fewer risks, fewer unanswered questions, and a better chance to reverse damage before it’s too late.

"In the end, liver health is about more than numbers on a chart—it’s about filtering the toxins of life, both literal and metaphorical. With elastography, medicine now has a window into the body’s resilience, offering hope that healing can be measured, validated, and celebrated." - Dr Robert L. Bard



References  

1. Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(5):1264-1281.e4. doi:10.1053/j.gastro.2018.12.036

2. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29(12):1705-1713. doi:10.1016/j.ultrasmedbio.2003.07.001

3. European Association for the Study of the Liver (EASL). EASL clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264. doi:10.1016/j.jhep.2015.04.006

4. World Health Organization. Cirrhosis. Published 2023. Accessed September 2025. https://www.who.int/news-room/fact-sheets/detail/cirrhosis

5. Boursier J, Zarski JP, de Ledinghen V, et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology. 2013;57(3):1182-1191. doi:10.1002/hep.25993

6. Wong VW, Adams LA, de Lédinghen V, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD and NASH — current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15(8):461-478. doi:10.1038/s41575-018-0014-9



COPYRIGHT NOTICE

This article draft is an original work produced by the writing and editorial team of the AngioInstitute (a 501(c)(3) nonprofit organization), created exclusively for use, distribution, and publication by DetoxScan.org. All content contained herein, including written material, concepts, titles, and formatting, is the intellectual property of the AngioInstitute and is protected under United States and international copyright laws. Unauthorized reproduction, copying, distribution, transmission, or republication of any portion of this material—whether in print, digital, or any other format—is strictly prohibited without prior written permission from the copyright holder. The AngioInstitute retains full ownership of the content until and unless formally transferred in writing. This draft may not be altered, adapted, or used in derivative works without express consent. All rights reserved. For inquiries regarding usage, permissions, or content licensing, please contact the AngioInstitute directly.


Saturday, September 27, 2025

VETERAN DOC'S RESEARCH ON OLD WOUNDS

 

PART 3:

Richard Signarino’s Checkup—and the Bigger Picture for Veterans Who Worked Around Aircraft

When Richard Signarino, a U.S.A.F. veteran who spent part of his service maintaining F-4C fighters, came to Dr. Robert L. Bard for a prostate health checkup, he brought more than routine concerns. Like many veterans who worked on flight lines or in hangars, he wondered whether years around jet fuel, solvents, radar systems, and other occupational exposures could affect long-term health—including prostate cancer risk. Dr. Bard’s exam used high-resolution ultrasound with Doppler and elastography to look beyond a PSA number, mapping gland architecture, vascularity, and any focal stiffness that might warrant follow-up. The scan offered Richard something too many veterans lack: a concrete, real-time picture of the prostate that helps separate worry from actionable findings.

What the research says about aircraft work and cancer

A large Department of Defense analysis of nearly 900,000 aircrew and aviation support personnel (1992–2017) found higher rates of several cancers compared with the general U.S. population. For men, the study reported a 16% higher rate of prostate cancer among aircrew; ground crews also showed elevated incidence for certain cancers. Mortality was lower overall—likely reflecting fitness and access to care—yet the incidence signal has prompted deeper investigation into aviation-related exposures and screening needs.¹

For those on the maintenance side, historical cohorts exposed to trichloroethylene (TCE)—a degreasing solvent widely used in aircraft repair—have been studied repeatedly. Extended follow-up of aircraft maintenance workers shows mixed results on all-cancer mortality, but TCE as a chemical has substantial epidemiologic literature linking it to several cancers; some studies and case evaluations include prostate cancer signals among broader cancer excesses.²⁻³,⁵

Another exposure class is jet fuels (JP-5/JP-8/Jet-A). The ATSDR toxicological profile and VA’s exposure pages summarize neurologic, respiratory, and dermal effects, with cancer associations still being clarified. A 2017 federal review concluded there is limited and inconsistent evidence for cancer risk specifically from jet fuels, underscoring the need for better exposure assessment and long-term follow-up.⁴

Concerns sometimes extend to radar and radiofrequency (RF) radiation. Meta-analyses and pooled evaluations generally do not show a significant increase in overall cancer risk from occupational radar exposure, though case series of young military patients have fueled calls for more granular exposure reconstruction.⁶

In recent years, PFAS (“forever chemicals”) contamination on military bases—often from AFFF firefighting foam—has raised new questions. The National Cancer Institute’s epidemiology group reports that elevated PFAS levels were not associated with increased aggressive prostate cancer in a large prospective analysis, though research continues and exposure scenarios for firefighters and base residents differ.⁷ VA notes potential PFAS exposures for military firefighters and some installations and provides guidance for concerned veterans.⁸

Finally, broader reviews have argued that military veterans should be specifically queried for exposure histories (solvents, fuels, shift work, burn pits, etc.) because several exposures are plausibly associated with prostate cancer risk—even when evidence is not yet definitive.²,³

What’s “publishable” now—without overstating the science

  • Aviation cohorts show a signal: DoD’s registry analysis reports elevated prostate cancer incidence among aircrew, with ongoing work to tease out the drivers (chemical, physical, circadian/shift-work, or combined).¹

  • Solvent exposure matters: TCE remains a credible mechanistic and epidemiologic concern from aircraft maintenance settings; it is reasonable to document and report solvent histories in occupational prostate health narratives.²⁻³,⁵

  • Jet fuel links are not settled: Health effects from JP-5/JP-8 are documented, but cancer associations are limited/inconsistent; any statement should be careful and evidence-proportional.⁴

  • Radar/RF evidence is mixed to null overall: You can note no clear overall increase in cancer from radar exposure in pooled analyses, while acknowledging data gaps in individual circumstances.⁶

  • PFAS is under study: No clear association with prostate cancer in a large NCI study, but exposure contexts vary, and federal/VA monitoring continues—appropriate to flag in occupational histories.⁷⁻⁸

Translating evidence into action for veterans

For veterans like Richard, the uncertainty can be frustrating. Dr. Bard’s approach is to pair exposure-aware history-taking with precision imaging:

  1. Document the exposures. Years/roles on the flight line, tasks (degreasing, fuel handling), PPE use, known base contaminants (PFAS lists), and any radiation-risk activities (which have VA “presumptive” pathways for certain cancers).

  2. Screen thoughtfully. PSA and DRE remain standard, but ultrasound adds immediate anatomy: hypoechoic nodules, capsular changes, and power Doppler can highlight suspicious vascular patterns; elastography quantifies focal stiffness. Imaging can triage who needs MRI or biopsy and help target any necessary sampling more precisely—reducing blind procedures and uncertainty.⁹

  3. Monitor longitudinally. For veterans with notable exposure histories but equivocal labs, serial ultrasound mapping offers a low-burden way to watch for change—aligning with the DoD study’s implication that some aviation roles may merit closer surveillance, even when absolute risks remain modest.¹

Where aircraft maintainers fit

Aircraft maintainers face a different exposure mix than pilots: more direct contact with solvents (TCE and others)fuels and exhaust, lubricants, and sometimes shift work. The classic maintenance-facility cohorts anchor much of what we know; while not all outcomes rise to statistical significance, they justify exposure documentation and preventive care.²⁻³,⁵

Back to Richard

For Richard, the take-home is clarity and a plan. His checkup with Dr. Bard delivered a baseline prostate map, correlated with his exposure history from F-14 service. If future labs change—or if new symptoms arise—he has a reference point to guide targeted follow-up rather than guesswork. More broadly, his case illustrates how veteran-centric prostate care should work:

  • Ask detailed exposure questions from day one.

  • Use imaging to reduce uncertainty and personalize next steps.

  • Report exposures in clinical notes and, where appropriate, VA claims, leveraging evolving federal guidance.

The science is still maturing, and not every exposure leaves a measurable imprint. But veterans deserve a standard of care that recognizes their unique histories. For aircraft workers, that means acknowledging credible risks (solvents), openly labeling uncertainties (jet fuels, RF, PFAS for prostate cancer), and deploying the best tools we have—like ultrasound—to catch problems early and keep more veterans like Richard on a healthy, informed path.

Educational content only; not a substitute for medical advice. If you’re a veteran with relevant exposures, talk with your clinician about screening and document your service history.


References

  1. Sigurdson AJ, Waters KM, Gaffney SG, et al. Incidence and mortality of cancer among military aircrew and aviation ground crew personnel. JAMA Netw Open. 2022;5(3):e220938. doi:10.1001/jamanetworkopen.2022.0938

  2. National Research Council (US) Committee on Human Health Risks of Trichloroethylene. Assessing the Human Health Risks of Trichloroethylene: Key Scientific Issues. Washington, DC: National Academies Press; 2006.

  3. Scott CS, Jinot J. Trichloroethylene and cancer: systematic and quantitative review of epidemiologic evidence for identifying hazards. Int J Environ Res Public Health. 2011;8(11):4238-4271. doi:10.3390/ijerph8114238

  4. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological Profile for Jet Fuels (JP-5, JP-8, Jet A). Atlanta, GA: US Department of Health and Human Services; 2017.

  5. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Trichloroethylene, Tetrachloroethylene, and Some Other Chlorinated Agents. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol 106. Lyon, France: International Agency for Research on Cancer; 2014.

  6. Blettner M, Schlehofer B, Samkange-Zeeb F, Berg G. Medical exposure to radiofrequency and extremely low-frequency electromagnetic fields and risk of cancer: review of epidemiological studies. Radiat Environ Biophys. 2009;48(1):1-11. doi:10.1007/s00411-008-0206-8

  7. Purdue MP, Lan Q, Baris D, et al. A prospective study of serum per- and polyfluoroalkyl substances and prostate cancer risk. Environ Health Perspect. 2023;131(2):27003. doi:10.1289/EHP11153

  8. Veterans Affairs Office of Public Health. Military exposures: PFAS. US Department of Veterans Affairs website. Updated 2023. Accessed September 14, 2025. https://www.publichealth.va.gov/exposures/pfas/index.asp

  9. Donovan JL, Hamdy FC, Lane JA, et al. Screening, detection, and treatment of prostate cancer: evidence from randomized trials. Lancet. 2016;387(10013):1227-1237. doi:10.1016/S0140-6736(15)01038-0


Thursday, August 14, 2025

CH10: READING BETWEEN THE ECHOES


THE EYE WITHIN

UNLOCKING THE HIDDEN LANGUAGE OF MEDICAL IMAGING

By: Lennard M. Goetze, Ed.D  

In an age when medical imaging technologies grow more advanced by the day, one truth remains unchanged: a scan is only as valuable as the mind interpreting it. The Eye Within pulls back the curtain on the art and science of diagnostic interpretation through the career and insights of Dr. Robert Bard—internationally recognized cancer imaging specialist, educator, and pioneer in ultrasound diagnostics.

This is not a book about machines; it is about mastery. Dr. Bard takes readers into the high-stakes environment of medical imaging, where detecting a shadow, reading a flow pattern, or recognizing a subtle shift in tissue texture can change a life. With clarity and precision, he explains how ultrasound—when wielded by an experienced interpreter—becomes more than a tool for capturing anatomy. It becomes a dynamic instrument for understanding disease behavior, predicting progression, and guiding treatment.

From evaluating elusive thyroid disorders to identifying aggressive cancers others might miss, Dr. Bard demonstrates the power of seeing beyond the image. His work exemplifies how structural detail, physiologic clues, and contextual patient information combine into a complete diagnostic picture. At its heart, The Eye Within is both an education and a call to action—urging the medical community to value interpretation as a central pillar of care. For clinicians, students, and health advocates, it is a masterclass in precision medicine. For patients, it is reassurance that in the right hands, every image tells a story—and the right interpreter knows exactly how to read it. 

 

Copyright © 2025- Hummingbird Medical Press / Lennard Goetze Publications. All rights reserved.



Sample Chapter:

READING BETWEEN THE ECHOES

Dr. Bard Interprets Thyroid Ultrasound

 

Introduction – The Eye That Reads Beyond the Image

In the evolving landscape of diagnostic imaging, technology has made breathtaking advances. Yet, as Dr. Robert Bard often reminds all his colleagues, “It’s not the probe, but the interpreter, that saves the patient.”

Ultrasound has become a preferred frontline tool for thyroid evaluation, particularly for identifying nodules, monitoring autoimmune conditions like Hashimoto’s disease, and managing hyperactive disorders such as Graves disease. But while many can operate the machine, very few can translate its subtle, often cryptic language into decisive clinical insight. Dr. Bard is one of those few—a master “ultrasound translator” who sees patterns, behaviors, and evolving risks invisible to most.

This observational session—built on a series of ten thyroid ultrasound slides provided by Dr. Angela Mazza—offers a rare glimpse into the process of real-time interpretation. Six images focus on thyroid nodules; the remaining highlight hallmark features of Hashimoto’s thyroiditis and Graves disease. As Dr. Bard examines each slide, he performs not merely an identification exercise, but an on-time analysis: assessing the surrounding anatomy, interpreting vascular and tissue signatures, and predicting potential outcomes.

Even in an era of AI-assisted imaging, this skill remains irreplaceable. Artificial intelligence can catalog shapes and colors, but it cannot yet replicate the human ability to weigh anatomical nuance, integrate patient history, evaluate the tumor’s ecosystem, and make forward-looking predictions. Interpretation—true interpretation—blends technology, clinical reasoning, and physiological understanding.


Dr. Angela Mazza introduces her scans of a patient, touring us into the THYROIDSCAN process.

Below are are Dr. Bard’s own notes, presented in the first person, refined for clarity and depth, reflecting his approach as both a diagnostician and educator.

Assessment 1: NODULES

 

Click to enlarge
Solid Growth Without Suspicious Calcifications

I begin with the skin layer clearly visible at the top, followed by the anterior neck musculature and, deeper, the thyroid itself. The lesion’s borders are smooth—always a favorable sign—and I see no suspicious microcalcifications. While microcalcifications are nonspecific, their presence can indicate tissue degeneration from rapid tumor growth and poor vascular supply. Here, the echo pattern is heterogeneous, meaning the texture varies within the nodule, which warrants closer review. Of particular academic interest is the posterior wall brightness—dimmer than the anterior—reflecting sound absorption by solid tissue. This “through transmission” loss can signal dense or heterogeneous pathology and is an important interpretive clue.

 

Click to enlarge
Simple Cyst with High Through Transmission

This image shows a well-circumscribed, cystic structure. The posterior border is brighter than the anterior because fluid allows sound to pass freely. Internal debris is visible—common in benign cysts and observable with high-resolution probes. Surrounding tissues are neither compressed nor invaded, suggesting no aggressive behavior. This is a prime example of strong through transmission, a useful differentiator between cystic and solid pathology.


Click to enlarge
Partially Cystic Complex Nodule
This lesion exhibits both solid and cystic components, the most common benign thyroid pattern but also possible in malignancies. The posterior border is again brighter due to the fluid component. On the left, I note the common carotid artery—its wall smooth and without plaque. When scanning thyroids, I always evaluate adjacent structures; lymph nodes and vessels often provide indirect clues to pathology.



Click to enlarge
Predominantly Solid Complex Nodule with Early Calcification

Here, the anterior and posterior borders are similar in brightness, suggesting limited fluid content. The heterogeneous echo texture and a small calcification at the cystic-solid interface may represent tumor degeneration. It’s important to remember that tumor enlargement during therapy does not always indicate progression—degenerating tumors can swell with fluid before shrinking.


 

 

Click to enlarge
Septated Complex Nodule with Macrocalcification

The lesion contains cystic and solid areas separated by septations, giving it a spongiform appearance. The macrocalcification is consistent with degenerative change. The bright posterior border confirms significant cystic degeneration—what I refer to as “internal cystic necrosis”—often a sign of tumor breakdown.

 


Assessment #2:  
THYROID CANCER    

 

Click to enlarge
Classic Ultrasound Signatures of Thyroid Cancer

In this case, credit must be given to Dr. Angela Mazza for her precise capture of a lesion demonstrating classic hallmarks of thyroid cancer. High-quality image acquisition is not accidental—it reflects an operator’s ability to optimize probe selection, angulation, and focal depth to reveal the lesion’s most telling features. This provides the interpreting radiologist with the complete visual data needed for an accurate assessment. One such feature is the presence of microcalcifications—tiny, punctate echogenic foci within the lesion. While not exclusively diagnostic of cancer, their occurrence often signals abnormal cellular turnover and tissue degeneration, making them an important red flag in the radiologist’s assessment.

A second hallmark is the firm, rigid texture of malignant tissue. I often describe it to students using the “steel analogy”: just as steel resists penetration, cancerous tissue offers a gritty, unyielding resistance to a biopsy needle. This hardness correlates with the tumor’s dense cellular structure and fibrotic reaction. Equally significant is the taller-than-wide dimension ratio. Benign nodules, when they grow, tend to expand laterally, developing smooth, encapsulated borders. Aggressive cancers, however, often invade vertically, crossing tissue planes. This vertical dominance is a subtle but critical diagnostic cue—used not only in thyroid cancer but also in breast oncology.

On ultrasound, malignancies typically appear hypoechoic—darker than the surrounding thyroid parenchyma—because the dense cellular mass absorbs more sound energy, allowing less to be reflected back to the transducer. This also results in a posterior acoustic shadow or a dimmer back border, further reinforcing the suspicion of a solid, infiltrative process. When these elements—microcalcifications, firmness, hypoechogenicity, vertical growth, and diminished posterior transmission—are observed together, they form a constellation of findings that strongly favor malignancy. The role of the interpreting radiologist is not simply t note these features, but to integrate them into a complete risk profile for each patient, guiding both urgency and strategy in clinical management.

 

Assessment 3: HASHIMOTO’S & GRAVES DISEASE

 

Click to enlarge
Hashimoto’s Thyroiditis

Hashimoto’s presents variably on ultrasound—sometimes uniform in echotexture, sometimes showing fibrotic stranding and mixed internal patterns. Routine thyroid blood panels can miss autoimmune-mediated inflammation, making ultrasound a critical adjunct. The gland may reveal fibrotic bands, patchy echogenic change, or small cystic areas depending on the stage of degeneration. In this case, the echo pattern is mixed, with no significant change in rear-wall brightness compared to normal thyroid tissue. Because through-transmission may remain unaltered, interpretation must be integrated with autoimmune-specific serology, patient symptoms, and disease history to achieve a confident diagnosis and guide long-term management.

 

 

Graves

Click to enlarge
Disease: Baseline B-Mode & with Color Doppler

Although Graves’ disease is not a form of cancer, it remains a significant thyroid condition because of its system-wide effects and marked increase in glandular blood flow. The overproduction of thyroid hormones accelerates metabolism across multiple organ systems, influencing cardiovascular function, skin changes, and general physiological balance. In grayscale (B-mode) ultrasound, the thyroid often presents with a uniform appearance, though areas of patchy irregularity from fibrotic change may be visible. Through-transmission typically mirrors that of normal tissue; however, the clearest diagnostic distinction emerges when color Doppler imaging is applied.

 

Under Doppler, Graves’ disease can display a pronounced surge in intrathyroidal vascularity, with smooth, branching blood vessels feeding an overactive gland. This striking visual signature—sometimes described as a “thyroid inferno”—serves not only as an identifier of disease activity but also as a guide for therapy. By following these vascular patterns over time, clinicians can fine-tune treatment plans and adjust dosages without invasive biopsies or radioactive scans.

 

 

THERMOLOGY: THE STRATEGIC FIRST STEP IN THYROID IMAGING

Before an ultrasound probe touches the skin, thermographic imaging can create a dynamic map of the thyroid’s physiologic activity. By detecting infrared heat patterns from the skin surface, thermology reveals areas of abnormal vascular activity—whether from inflammation, autoimmune flare, or tumor-driven angiogenesis. This non-contact, radiation-free technique serves as an early “scout,” directing the sonographer’s focus to regions most likely to harbor disease.

 

When paired with ultrasound, thermology’s surface heat mapping complements sonography’s deeper structural view. Elevated heat zones may correspond to hypervascular nodules in Graves’ disease or inflammatory patterns in Hashimoto’s, while cooler areas may signal cystic or fibrotic changes. Beyond detection, thermal assessment can monitor treatment response—declines in both vascularity and gland temperature often indicate therapy is working. 

In skilled hands, this dual-modality approach—thermology for physiologic mapping and ultrasound for structural definition—offers a fast, noninvasive, and highly precise pathway for diagnosis, monitoring, and personalized thyroid care.

 

CONCLUSION – A PARTNERSHIP IN PRECISION

Dr. Bard’s review of Dr. Angela Mazza’s thyroid ultrasound cases demonstrates why expertise in interpretation remains indispensable. Every scan is more than an image—it is a layered narrative of structure, function, and evolving physiology. By coupling her deep endocrinology expertise with ultrasound as a primary diagnostic tool, Dr. Mazza ensures her patients receive assessments that are both scientifically rigorous and dynamically responsive.

In an age where algorithms threaten to overshadow human judgment, this collaboration underscores an enduring truth: the best outcomes emerge when skilled imaging interpretation meets the informed clinical context of a specialist who understands the whole patient.

 

 COPYRIGHT NOTICE

This article draft is an original work produced by the writing and editorial team of the AngioInstitute (a 501(c)(3) nonprofit organization), created exclusively for use, distribution, and publication by DetoxScan.org. All content contained herein, including written material, concepts, titles, and formatting, is the intellectual property of the AngioInstitute and is protected under United States and international copyright laws. Unauthorized reproduction, copying, distribution, transmission, or republication of any portion of this material—whether in print, digital, or any other format—is strictly prohibited without prior written permission from the copyright holder. The AngioInstitute retains full ownership of the content until and unless formally transferred in writing. This draft may not be altered, adapted, or used in derivative works without express consent. All rights reserved. For inquiries regarding usage, permissions, or content licensing, please contact the AngioInstitute directly.


Revisiting Asbestos Related Injuries (and other toxic contaminants)

 PRESS RELEASE  DETOXSCAN™ Program to Cover Diagnostic Front in Environmental Exposure Care New York , NY (October 2025) — Twenty-fou...